MicroRNAs (miRNAs) are small, non-coding RNA molecules that regulate gene expression post-transcriptionally. As a consequence of their function towards mRNA, miRNAs are widely associated with the pathogenesis of several human diseases, making miRNAs a target for new therapeutic strategies based on the control of their expression. 

The downregulation of SIRT6 by miRNAs has been implicated in several disease processes, including cancer, cardiovascular diseases, metabolic disorders, and neurodegenerative diseases. Dysregulation of SIRT6 levels disrupt cellular homeostasis and contribute to the development and progression of these age-related conditions.

At SirtLab, we employ an innovative “miRacle” strategy by utilizing a dual anti-miRNA approach to maximize the therapeutic benefits of targeting SIRT6 mRNA molecules. Our dual anti-miRNA approach led to an additive effect on the regulation of SIRT6 mRNA and allows a significant reduction in the required dose of each individual anti-miRNA, minimize potential off-target effects and enhance the safety profile of the treatment, increasing its overall tolerability.